Trial · NCT00807027

Clinical Trial to Assess the Efficacy and Safety of 'Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea

NCT00807027, Phase 3, Completed, GC Cell Corporation; results first posted 2025-10-10

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Clinical Trial to Assess the Efficacy and Safety of 'Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea. Trials, record NCT00807027. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00807027

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Clinical Trial to Assess the Efficacy and Safety of 'Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea
NCT number: NCT00807027
Status: Completed
Phases: Phase 3
Enrollment: 180 participants, actual
Lead sponsor: GC Cell Corporation
Conditions: Glioblastoma
Interventions: Activated T lymphocyte(Immuncell-LC)
First posted: 2008-12-11
Last updated: 2025-10-10
Results first posted: 2025-10-10

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Progression-free Survival(PFS)	From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 46 months.	Progression-free survival was assessed locally by investigators on the basis of enhanced MRI was performed approximately 4 weeks after chemoradiotherapy, then at 10, 22, 34 and 46 weeks after randomization, and every 3\~12 months thereafter during the follow-up phase.
Secondary	Overall Survival(OS)	From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 46 months.

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Progression-free Survival(PFS)	From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 46 months.		months	MEDIAN
SECONDARY	Overall Survival(OS)	From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 46 months.		months	MEDIAN

Source ClinicalTrials.gov

Results by group4

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Progression-free Survival(PFS)	Control Group	5.4	95% Confidence Interval 3.3 to 7.9	months
Progression-free Survival(PFS)	CIK Immunotherapy Group	8.1	95% Confidence Interval 5.8 to 8.5	months
Overall Survival(OS)	Control Group	16.88	95% Confidence Interval 13.91 to 21.94	months
Overall Survival(OS)	CIK Immunotherapy Group	22.47	95% Confidence Interval 17.20 to 23.85	months

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Control Group	89
Overall Study	STARTED	CIK Immunotherapy Group	91
Overall Study	COMPLETED	Control Group	73
Overall Study	COMPLETED	CIK Immunotherapy Group	74
Overall Study	NOT COMPLETED	Control Group	16
Overall Study	NOT COMPLETED	CIK Immunotherapy Group	17

Source ClinicalTrials.gov

Adverse events844

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Nausea	Gastrointestinal disorders	Control Group	52	89	90
other	Nausea	Gastrointestinal disorders	Test Group	46	91	92
other	Constipation	Gastrointestinal disorders	Control Group	31	89	40
other	Constipation	Gastrointestinal disorders	Test Group	32	91	40
other	Vomiting	Gastrointestinal disorders	Control Group	28	89	46
other	Vomiting	Gastrointestinal disorders	Test Group	34	91	65
other	Dyspepsia	Gastrointestinal disorders	Control Group	20	89	28
other	Dyspepsia	Gastrointestinal disorders	Test Group	16	91	24
other	Diarrhoea	Gastrointestinal disorders	Control Group	8	89	9
other	Diarrhoea	Gastrointestinal disorders	Test Group	17	91	18

1 to 10 of 844Source ClinicalTrials.gov

See all 844 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Control Group	52	89
Total, all-cause mortality	Test Group	51	91
Total, other adverse events	Control Group	83	89
Total, other adverse events	Test Group	84	91
Total, serious adverse events	Control Group	31	89
Total, serious adverse events	Test Group	35	91

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Test Group vs Control Group: deaths from any cause	Trial comparisons
Test Group vs Control Group: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00807027

GET https://conductscience.org/api/trials/v1/NCT00807027/events?page=2

API reference For AI assistants